{
  "nctId": "NCT02675426",
  "briefTitle": "A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone",
  "officialTitle": "A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs",
  "protocolDocument": {
    "nctId": "NCT02675426",
    "filename": "Prot_002.pdf",
    "label": "Study Protocol",
    "date": "2020-11-25",
    "uploadDate": "2023-02-20T16:46",
    "size": 2098483,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02675426/document/Prot_002.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "QUADRUPLE",
  "enrollmentInfo": {
    "enrollmentCount": 661,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2015-12-17",
    "completionDate": "2022-03-10",
    "primaryCompletionDate": "2017-04-21",
    "firstSubmitDate": "2015-12-11",
    "firstPostDate": "2016-02-05"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Adult male or female, at least 18 years old.\n* Diagnosis of rheumatoid arthritis (RA) for greater than or equal to 3 months.\n* Subjects have been receiving conventional synthetic DMARD (csDMARD) therapy for greater than or equal to 3 months and on a stable dose for greater than or equal to 4 weeks prior to the first dose of study drug. The following csDMARDs are allowed: methotrexate (MTX), sulfasalazine, hydroxychloroquine, chloroquine, and leflunomide.\n* Meets the following minimum disease activity criteria: greater than or equal to 6 swollen joints (based on 66 joint counts) and greater than or equal to 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits.\n* Subjects with prior exposure to at most one biologic DMARD (bDMARD) may be enrolled (up to 20% of study population) if they have documented evidence of intolerance to bDMARDs or limited exposure (less than 3 months) and have satisfied required washout periods.\n\nExclusion Criteria:\n\n* Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib).\n* History of inflammatory joint disease other than RA. History of secondary Sjogren's Syndrome is permitted.\n* Subjects who are considered inadequate responders to bDMARD therapy as determined by the Investigator.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12",
        "description": "The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:\n\n1. ≥ 20% improvement in 68-tender joint count;\n2. ≥ 20% improvement in 66-swollen joint count; and\n3. ≥ 20% improvement in at least 3 of the 5 following parameters:\n\n   * Physician global assessment of disease activity;\n   * Patient global assessment of disease activity;\n   * Patient assessment of pain;\n   * Health Assessment Questionnaire - Disability Index (HAQ-DI);\n   * High-sensitivity C-reactive protein (hsCRP).",
        "timeFrame": "Baseline and Week 12"
      },
      {
        "measure": "Percentage of Participants Achieving Low Disease Activity (LDA) Based on DAS28(CRP) at Week 12",
        "description": "The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes was low disease activity, based on a Disease Activity Score 28 (DAS28)-CRP score of ≤ 3.2 at Week 12.\n\nThe DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.\n\nA DAS28 score less than or equal to 3.2 indicates low disease activity.",
        "timeFrame": "Week 12"
      }
    ],
    "secondary": [
      {
        "measure": "Change From Baseline in in Disease Activity Score 28 (CRP) at Week 12",
        "description": "The DAS28 is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity. A negative change from Baseline in DAS28 (CRP) indicates improvement in disease activity.",
        "timeFrame": "Baseline and Week 12"
      },
      {
        "measure": "Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) at Week 12",
        "description": "The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire that measures the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and errands and chores) over the past week. Participants assessed their ability to do each task on a scale from 0 (without any difficulty) to 3 (unable to do). Scores were averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 represents very severe, high-dependency disability.\n\nA negative change from Baseline in the overall score indicates improvement.",
        "timeFrame": "Baseline and Week 12"
      },
      {
        "measure": "Change From Baseline in Short-Form 36 (SF-36) Physical Component Summary (PCS) Score at Week 12",
        "description": "The Short Form 36-Item Health Survey (SF-36) Version 2 is a self-administered questionnaire that measures the impact of disease on overall quality of life during the past 4 weeks. The SF-36 consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health).\n\nThe physical component summary score is a weighted combination of the 8 subscales with positive weighting for physical functioning, role-physical, bodily pain, and general health. The PCS was calculated using norm-based scoring so that 50 is the average score and the standard deviation equals 10. Higher scores are associated with better functioning/quality of life; a positive change from Baseline score indicates an improvement.",
        "timeFrame": "Baseline and Week 12"
      },
      {
        "measure": "Percentage of Participants Achieving Clinical Remission Based on DAS28 (CRP) at Week 12",
        "description": "Clinical remission (CR) based on DAS28 (CRP) is defined as achieving a DAS28 (CRP) of less than 2.6.\n\nDAS28 (CRP) is a composite index used to assess rheumatoid arthritis disease activity, calculated based on the tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), Patient's Global Assessment of Disease Activity (0-100), and hsCRP (in mg/L). Scores on the DAS28 range from 0 to approximately 10, where higher scores indicate more disease activity.",
        "timeFrame": "Week 12"
      },
      {
        "measure": "Percentage of Participants Achieving Low Disease Activity Based on CDAI at Week 12",
        "description": "Low disease activity based on the clinical disease activity index (CDAI) is defined as a CDAI score ≤ 10.\n\nCDAI is a composite index for assessing disease activity based on the summation of the total tender joint count (out of 28 evaluated joints), swollen joint count (out of 28 evaluated joints), patient global assessment of disease activity measured on a VAS from 0 to 10 cm, and physician global assessment of disease activity measured on a VAS from 0 to 10 cm. The total CDAI score ranges from 0 to 78 with higher scores indicating higher disease activity.",
        "timeFrame": "Week 12"
      },
      {
        "measure": "Change From Baseline in Duration of Morning Stiffness at Week 12",
        "description": "Participants were asked to indicate the time it took for them to get as limber as possible after awakening with morning stiffness over the past 7 days.",
        "timeFrame": "Baseline and Week 12"
      },
      {
        "measure": "Change From Baseline in in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) at Week 12",
        "description": "The FACIT-Fatigue scale is a 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a five point Likert scale from 0 (not at all) to 4 (very much). The FACIT-Fatigue scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from Baseline indicates improvement.",
        "timeFrame": "Baseline and week 12"
      },
      {
        "measure": "Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 12",
        "description": "Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR50 response criteria:\n\n1. ≥ 50% improvement in 68-tender joint count;\n2. ≥ 50% improvement in 66-swollen joint count; and\n3. ≥ 50% improvement in at least 3 of the 5 following parameters:\n\n   * Physician global assessment of disease activity;\n   * Patient global assessment of disease activity;\n   * Patient assessment of pain;\n   * Health Assessment Questionnaire - Disability Index (HAQ-DI);\n   * High-sensitivity C-reactive protein (hsCRP).",
        "timeFrame": "Baseline and Week 12"
      },
      {
        "measure": "Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 12",
        "description": "Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR70 response criteria:\n\n1. ≥ 70% improvement in 68-tender joint count;\n2. ≥ 70% improvement in 66-swollen joint count; and\n3. ≥ 70% improvement in at least 3 of the 5 following parameters:\n\n   * Physician global assessment of disease activity;\n   * Patient global assessment of disease activity;\n   * Patient assessment of pain;\n   * Health Assessment Questionnaire - Disability Index (HAQ-DI);\n   * High-sensitivity C-reactive protein (hsCRP).",
        "timeFrame": "Baseline and Week 12"
      },
      {
        "measure": "Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1",
        "description": "Participants who met the following 3 conditions for improvement from Baseline were classified as meeting the ACR20 response criteria:\n\n1. ≥ 20% improvement in 68-tender joint count;\n2. ≥ 20% improvement in 66-swollen joint count; and\n3. ≥ 20% improvement in at least 3 of the 5 following parameters:\n\n   * Physician global assessment of disease activity;\n   * Patient global assessment of disease activity;\n   * Patient assessment of pain;\n   * Health Assessment Questionnaire - Disability Index (HAQ-DI);\n   * High-sensitivity C-reactive protein (hsCRP).",
        "timeFrame": "Baseline and Week 1"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 10,
      "otherCount": 0,
      "totalCount": 12
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 99,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:58.150Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}